PHS
INBX icon

PFM Health Sciences’s Inhibrx INBX Stock Holding History

PFM Health Sciences’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2M Buy
308,385
+2,954
+1% +$296K 2.51% 8
2026
Q1 		$20.5M Buy
305,431
+39,914
+15% +$2.96M 1.87% 14
2025
Q4 		$21M Buy
265,517
+25,873
+11% +$1.76M 2.09% 15
2025
Q3 		$8.07M Sell
239,644
-4,617
-2% -$114K 0.62% 43
2025
Q2 		$3.49M Sell
244,261
-195,022
-44% -$2.52M 0.3% 46
2025
Q1 		$6.15M Buy
439,283
+303,737
+224% +$4.12M 0.45% 40
2024
Q4 		$2.09M Hold
135,546
– – 0.13% 72
2024
Q3 		$2.12M Hold
135,546
– – 0.12% 67
2024
Q2 		$1.92M Buy
+135,546
New +$2.12M 0.1% 71

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PFM Health Sciences's INBX Position: Q2 2026 in Review

PFM Health Sciences increased its Inhibrx (INBX) stake by 0.97% in Q2 2026, buying an estimated $296K and bringing the position to 308,385 shares worth $29.2M. The position accounts for 2.51% of the portfolio, ranked #8.

PFM Health Sciences first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • PFM Health Sciences held 308,385 shares of Inhibrx worth $29.2M as of Q2 2026.
  • PFM Health Sciences bought 2,954 Inhibrx shares in Q2 2026, an estimated $296K.
  • Inhibrx made up 2.51% of PFM Health Sciences's portfolio in Q2 2026, its #8 holding.
  • PFM Health Sciences first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.